VENLO, The Netherlands, May 16 /PRNewswire-FirstCall/ -- Qiagen N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins today announced that it has obtained an exclusive license from Procognia Limited to market and sell Procognia's proprietary "on-chip" protein glycoanalysis technology. The company believes the new products based on Procognia's technology to be an excellent enhancement of its successfully launched Qproteome protein fractionation product line, which addresses a range of different applications in life science research, including drug development and clinical research. Procognia's "on-chip" glycoanalysis products consist of lectin chips and analytical software developed and manufactured by Procognia. These products will be combined with a selection of Qiagen's QProteome product line to create novel, "guided fractionation" solutions which should address previously unmet needs in proteomics and systems biology. Qiagen believes that this novel protein glycoanalysis technology addresses a previously unmet need for the preparation and understanding of proteins in the rapidly emerging field of glycomics. Financial terms were not disclosed.
In January 2005, Qiagen began a new area of technology leadership in protein sample preparation with the launch of its QProteome product line. This new offering integrates state-of-the-art technologies into the broadest portfolio of consumable products for the fractionation, enrichment and depletion of target protein classes. A significant number of protein classes (fractions) are differentiated from each other by modifications incurred during protein synthesis. One such modification is the addition of highly variable oligosaccharide chains (glycans). Today, a significant area of research is focused on these glycosylated proteins (glycomics) as glycosylation influences folding, function, specificity and activity of a protein. Procognia's technology creates a new dimension in differentiation of the glycosylation patterns of proteins and thereby allows further sub-fractionation of the target proteins, providing significantly higher resolution than previously possible.
The agreement announced today significantly expands the leadership of the Qproteome line with exclusive access to Procognia's novel and proprietary "on-chip" glycoanalysis technology for glycosylated proteins. By combining this technology with its QProteome product line, Qiagen offers a solution which for the first time enables the customer to quickly standardize and optimize their glycomic sample workflow with easy to use consumables.
"By integrating Procognia's "on-chip" glycoanalysis into our Qproteome line, we are creating novel "guided-fractionation" solutions for the exciting field of glycomics", said Peer Schatz, Qiagen's Chief Executive Officer. "We expect this technology to significantly accelerate Qiagen's leadership in preanalytical solutions in this rapidly growing area of proteomics."
"We are pleased that Qiagen has chosen Procognia as its commercial partner", said Ron Long, Chairman and CEO of Procognia. "Combining Procognia's novel glycoanalysis with Qiagen's existing QProteome product lines will lead to significant advances in protein science."
Qiagen N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. Qiagen has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. Qiagen's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, Qiagen is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. Qiagen employs more than 1,300 people worldwide. Further information on Qiagen can be found at http://www.qiagen.com/.
Procognia Ltd, a 2004 World Economic Forum Technology Pioneer award winner, is focused on developing and commercializing its cutting edge proprietary technologies to enable the unraveling of disease mechanisms and the discovery and development of drugs to treat those diseases. In addition to developing its glycoanalysis technology, Procognia has developed arrays of biologically related proteins that retain their physiological function in the array format. Procognia was formed in April 2002 with a corporate headquarters and manufacturing in Maidenhead, United Kingdom. Commercial operations are run from the United Kingdom and Exton, PA, United States, and supported by R&D facilities in Maidenhead, United Kingdom and Ashdod, Israel. Further information on Procognia can be found at http://www.procognia.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to Qiagen's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Qiagen's, products (including fluctuations for certain events including funding, budgets, and others), difficulties in successfully adapting Qiagen's products to integrated solutions and producing such products, the ability of Qiagen to identify and develop new products and to differentiate its products from competitors, market acceptance of Qiagen's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that Qiagen has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
CONTACT: Contacts: Peer M. Schatz, Chief Executive Officer, Qiagen N.V.,+49-2103-2911-702, e-mail: peer.schatz@Qiagen.com; Dr. SolveighMahler, Director of Investor Relations, Qiagen N.V.,+49-2103-2911-710, e-mail: solveigh.maehler@Qiagen.com; Dr.Achim Ribbe, Executive Director Corporate, BusinessDevelopment, Qiagen GmbH, +49-2103-2916-264, e-mail:achim.ribbe@QIAGEN.com; Ron Long, Chief Executive Officer,Procognia Ltd, +44-1628-513501, e-mail: ron.long@PROCOGNIA.com;Sue Cotrel, VP Marketing, Procognia Ltd, +44(0)1628-513503,e-mail: sue.cotrel@Procognia.com; Nicholas Sleep, Head ofBusiness Development, Procognia Ltd, +44(0)1628-513500, e-mail:nicholas.sleep@Procognia.com